Zevra Q1 2026 revenue rises 78% to $36.2 million; net income $37.9 million
Zevra Therapeutics reported first-quarter 2026 net revenue of $36.2 million, up from $20.4 million a year earlier, and net income of $37.9 million, compared with a net loss of $3.1 million in Q1 2025. The profit includes a one-time $43.3 million gain on the $50.0 million sale of its SDX portfolio to Commave Therapeutics, and the company prepaid its $63.1 million term loan in full.
Key points
- Net revenue of $36.2 million for Q1 2026, versus $20.4 million in Q1 2025.
- Net income of $37.9 million, or $0.60 per diluted share, versus a net loss of $3.1 million in Q1 2025.
- Excluding one-time items, the company estimated adjusted net income of $11.5 million, or $0.18 per diluted share (non-GAAP).
- Cash, cash equivalents and securities were $236.8 million as of March 31, 2026.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.